Delfi Diagnostics reported clinical utility data for its cfDNA-based FirstLook Lung liquid biopsy assay, showing increased lung cancer screening participation in a cluster-randomized interventional FIRSTLUNG trial. In nearly 3,000 patients who were behind on screening across 28 clinics, the test showed 80% sensitivity and 56% specificity, with a negative predictive value of 99.8%. Delfi said access to FirstLook Lung nearly tripled overall screening of any kind and increased LDCT screening by about 1.5-fold. The company also reported that many cancers detected through the pathway were stage I, potentially expanding treatment options for patients eligible for curative approaches. The company has submitted results for peer review and described modeling showing that incremental adoption could prevent additional deaths in a hypothetical simulated U.S. population—anchoring the business case around real-world screening behavior rather than test performance alone.